UNSPSC 51284107: Cefmenoxime

This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KBZ4844CXN. European Medicines Agency schedules Cefmenoxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07397MIG. Cefmenoxime generally arises in the molecular formula C16H17N9O5S3.

UNSPSC 51284107 Cefmenoxime, a Commodity code, shows minimal recent state and local procurement activity directly aligned with the code's nominal scope. The two opportunities surfaced in the recent record—an Illinois Department of Public Health pharmaceutical warehouse contract awarded to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride, and a Seminole County, Florida IFB for Naloxone and drug deactivation systems—do not involve cefmenoxime procurement. State and local governments appear to be buying antibiotics and emergency-response pharmaceuticals through cooperative purchasing vehicles (MMCAP Infuse consortium) and competitive sealed bidding, but the code does not capture meaningful recent demand for cefmenoxime itself as a line item.

Geographic activity touching tangentially related pharmaceutical categories spans Illinois and Florida, but these are not solicitations under the cefmenoxime code. The Illinois award, completed in August 2026 with a $2,999,999.11 total value over 12 months plus two renewal options, demonstrates that state health departments pursue multi-year pharmaceutical contracts through established cooperative frameworks. Seminole County's July 2026 IFB for naloxone (1,900 units annually) and safe drug deactivation systems (800 units annually) shows municipal and county interest in emergency pharmaceuticals with structured renewal terms and FEMA compliance. Business development professionals evaluating this code should note that recent state and local procurement tagged under cefmenoxime does not reflect active market demand; wider pharmaceutical commodity codes covering broad antibiotic families may be more productive for firms seeking state and local health-sector volume.